<DOC>
	<DOC>NCT00617123</DOC>
	<brief_summary>This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).</brief_summary>
	<brief_title>Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Vorapaxar</mesh_term>
	<criteria>Evidence or a history of atherosclerosis involving the coronary, cerebral, or peripheral vascular systems The study will include participants who meet none of the exclusion criteria for the parent protocol (P04737) and also the following: history or evidence of agerelated macular degeneration on baseline evaluation history of diabetic macular edema, or evidence of treated diabetic retinopathy on baseline evaluation history or evidence of other retinal diseases, including retinal injury, on baseline evaluation history or evidence of retinal surgery, including laser photocoagulation, on baseline evaluation history or evidence of glaucoma on baseline evaluation history or evidence of high intraocular pressure of &gt;22 mm Hg on baseline evaluation evidence of center foveal thickness of &gt;190 µm on baseline OCT examination presence of vacuoles in the retina on baseline OCT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>